AKTS
Aktis OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
AKTS vs peer average
46/100
AKTS vs. peer average (D vs. D)
Grade spread
B 1 · C 1 · D 6 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
CGEM is the first available peer comparator.
Development-stage oncology context at a similar supplied market capitalization, but the packet does not establish comparable radiopharmaceutical programs, targets or trial milestones; not a direct valuation peer.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
AKTS
Aktis Oncology
CGEM
Cullinan Therapeutics
Grade
D
D
Momentum
8
12
Value
46
41
Sentiment
61
55
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs CGEM
AKTS / CGEM
Grade Position
In line
AKTS vs. peer average (D vs. D)
46/100
Momentum
8
CGEMValue
46
AKTSSentiment
61
AKTSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs AKTS
CGEM is the first peer returned for this comparison set.